3
3
Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
T7029 |
Pseudolaric Acid C
|
Antifungal | Microbiology/Virology |
Pseudolaric Acid C 是一种从Pseudolarix kaempferiGorden 根皮部中分离的二萜酸,对白色念珠菌有较弱的抗真菌活性。 | |||
T13851 |
Pseudolaric Acid C2
|
Others | Others |
Pseudolaric Acid C2 是一种从 Pseudolarix kaempferi 二萜酸,是大鼠口服和静脉注射后血浆、尿液、胆汁和粪便中 Pseudolaric acid B 的特异性代谢产物。 | |||
T81363 |
Pseudolaric acid C2-O-β-D-glucoside
|
||
Pseudolaric acid C2-O-β-D-glucoside, 一种天然产物,来源于Pseudolarix kaempferi,并通过分离提取得到。 |
Cat. No. | Product Name | Species | Expression System |
---|---|---|---|
TMPK-01450 |
HLA-C*03:04&B2M&KRAS G12D (GADGVGKSAL) Monomer Protein, Human, MHC (His & Avi), Biotinylated
KRAS1,MHC,K-RAS4B,KRAS,CFC2,K-RAS... |
Human | HEK293 Cells |
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail. | |||
TMPK-01456 |
HLA-C*03:04&B2M&KRAS G12D (GADGVGKSAL) Tetramer Protein, Human, MHC (His & Avi)
KRAS2,NS,MHC,C-K-RAS,KRAS1,K-RAS2A,K-RAS2B... |
Human | HEK293 Cells |
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail. | |||
TMPK-01451 |
HLA-C 03:04&B2M&KRAS G12D (GADGVGKSAL) Monomer Protein, Human, MHC (His & Avi)
NS3,K-RAS4A,K-Ras 2,NS,KRAS1,RASK2,MHC,KI-RAS,KRAS,... |
Human | HEK293 Cells |
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail. |